Application of TRPV4 ion channel as drug target in organophosphorus compound poisoning

• Main Authors: WANG SHUAI, LUO YUAN, WANG YONG'AN, YANG YANG, SUI XIN, YANG JUN, QIAO SIMO
• Format: Patent
• Language: Chinese; English
• Published: 23.10.2020
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

The invention discloses an application of a TRPV4 ion channel as a drug target in organophosphorus compound poisoning. A medicine is a TRPV4 inhibitor. The medicine comprises: pharmacological antagonists of TRPV4 including GSK2193874, HC-067047, GSK205, GSK3395879, RN-1734 and GSK2798745, a blocking type antibody of the TRPV4, siRNA of the TRPV4 and the like. The important point of the invention is that the TRPV4 is found to be closely related to brain injury caused by the organophosphorus compound poisoning; and the TRPV4 antagonists or the siRNA inhibits intracellular calcium flow caused bythe organophosphorus compound poisoning and NMDA receptor-mediated excitatory toxicity, so that the nervous system toxic effect induced by poisoning of two organophosphorus compounds including oxophosphorus and soman is remarkably reduced at both in-vivo and in-vitro levels. Therefore, the invention provides a new drug target for prevention and treatment of the organophosphorus compound poisoning,and provides a new strate